What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
James Larkin spends much of his time researching Internal medicine, Melanoma, Surgery, Ipilimumab and Nivolumab.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Oncology.
His biological study spans a wide range of topics, including Survival rate, Cancer and Survival analysis.
His Surgery research integrates issues from Binimetinib, Adverse effect and Urology.
His Ipilimumab research focuses on subjects like Cutaneous melanoma, which are linked to Malignancy, Pooled analysis, Mucosal melanoma and Mucous membrane.
He interconnects Axitinib, Pediatrics and Retrospective cohort study in the investigation of issues within Nivolumab.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. (5361 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Melanoma, Renal cell carcinoma and Ipilimumab.
His research on Internal medicine often connects related areas such as Surgery.
His Surgery research includes themes of Gastroenterology and Hazard ratio.
As part of one scientific family, James Larkin deals mainly with the area of Oncology, narrowing it down to issues related to the Cancer, and often Pharmacology and Immune system.
James Larkin focuses mostly in the field of Melanoma, narrowing it down to matters related to Trametinib and, in some cases, MEK inhibitor.
His work carried out in the field of Ipilimumab brings together such families of science as Pembrolizumab, Progression-free survival and Adjuvant therapy.
He most often published in these fields:
- Internal medicine (64.94%)
- Oncology (51.88%)
- Melanoma (32.02%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (64.94%)
- Oncology (51.88%)
- Melanoma (32.02%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Melanoma, Cancer and Renal cell carcinoma.
His study in the fields of Pembrolizumab, Ipilimumab, Nivolumab and Clinical trial under the domain of Internal medicine overlaps with other disciplines such as In patient.
His research on Ipilimumab frequently connects to adjacent areas such as Gastroenterology.
The study incorporates disciplines such as Clinical endpoint and Clear cell renal cell carcinoma in addition to Nivolumab.
His Oncology study combines topics from a wide range of disciplines, such as Advanced melanoma, Adverse effect, Immune checkpoint inhibitors and Phases of clinical research.
His study looks at the intersection of Melanoma and topics like Immunotherapy with Targeted therapy.
Between 2018 and 2021, his most popular works were:
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (692 citations)
- Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine (594 citations)
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (244 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Disease
James Larkin mainly focuses on Internal medicine, Oncology, Hazard ratio, Clinical trial and Cancer.
His study looks at the relationship between Internal medicine and fields such as Placebo, as well as how they intersect with chemical problems.
His Oncology research focuses on Melanoma and how it connects with Immunotherapy.
His Hazard ratio research is multidisciplinary, incorporating elements of Interim analysis, Clinical endpoint and Breast cancer.
His Phases of clinical research study deals with Ipilimumab intersecting with Adjuvant therapy.
His Randomized controlled trial study integrates concerns from other disciplines, such as Survival rate and Progression-free survival.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
